THE-NAGA-GROUP-AG
The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the All-in-One Financial SuperApp NAGA, cordially invites analysts, investors, shareholders as well as media and partners to virtually join its Capital Markets Day on 11 July 2024, 16.00 CEST. The 2024 Capital Markets Day will provide valuable insights into the strategic vision and growth ambitions of the NAGA Group.
Octavian Patrascu, the newly appointed CEO of the NAGA Group, will host the Virtual 2024 Capital Markets Day and elaborate on the Company's latest achievements, its plans for the future, and the innovative path the Group is forging.
KEY TOPICS
- Company Performance: H1 2024 financial results and milestones
- Merger with CAPEX.com: Strategic rationale, designed to enhance financial efficiency and market presence
- Innovation and Technology: CEO Octavian Patrascu on his vision for the Group, including the rollout of the NAGA SuperApp
- Future Plans: Upgrades to NAGA’s app and ecosystem, focusing on user experience, AI integrations, and empowering users to create their own financial instruments
The NAGA Group 2024 Capital Markets Day will be held virtually. In addition to the presentation in English, a German translation will be provided. The presentation will be followed by a Q&A session.
REGISTRATION
To register for the virtual 2024 Capital Markets Day, please click here.
Following the event, information will be made available in the Investor Relations section of the company's website, which can be found here. This will include a PDF file with the presentation, a full recording of the live event, and additional supporting materials.
About NAGA
NAGA is a leading German Fintech Company offering a SuperApp with the aim to merge social trading, investing in stocks, crypto, and neo banking into one unified platform, powered by its proprietary advanced technology. Operating in over 100 countries with 9 local offices, NAGA offers a diverse range of services for both fiat and cryptocurrencies. The platform features a physical VISA card with fiat and automatic crypto conversion plus cashback, dynamic social feeds, and advanced autocopy functions, enabling users to replicate the strategies of successful traders. Designed for a global community, NAGA provides an inclusive and efficient financial ecosystem for personal finance and trading.
| Language: | English | |
| Company: | The NAGA Group AG | |
| Hohe Bleichen 12 | ||
| 20354 Hamburg | ||
| Germany | ||
| E-mail: | info@naga.com | |
| Internet: | www.naga.com | |
| ISIN: | DE000A161NR7 | |
| WKN: | A161NR | |
| Indices: | Scale 30 | |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart, Tradegate Exchange | |
| EQS News ID: | 1928071 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619170454/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business1.12.2025 08:00:00 CET | Press release
The deal strengthens Regnology’s leadership in compliance technology, expands capabilities in risk and finance, and reinforces its commitment to innovation and client continuity. Regnology, a global leader in regulatory reporting and supervisory technology, today announces the successful closing of its acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) business. This milestone reinforces Regnology’s position as the trusted partner for financial institutions and regulators worldwide, delivering smarter, faster compliance solutions at scale. Regnology is committed to ensuring business continuity for all FRR clients. With a proven track record in seamless migrations and a unified data model on a scalable SaaS platform, institutions can maintain compliance securely and efficiently throughout the integration process. The acquisition underscores Regnology’s vision to combine regulatory expertise with innovation. The recently launched RRH Ascend platform exemplifies th
Ant International Upgrades Antom Copilot to Advance Domain-Specific Agentic AI to Solve Global Payment Complexity1.12.2025 07:21:00 CET | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced major upgrades to Antom Copilot, its industry-first AI agent designed for merchant payment and operations management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251130027598/en/ Antom Copilot supports a wide range of merchant payment operations and responds to early signs of issues with tailored recommendations. Integrated into the Antom Merchant Portal, Antom Copilot now provides enhanced automation and tailored assistance based on learnings from real-world cases, to help merchants handle payment complexity more efficiently. Main features include: Agentic support for entire payment lifecycle, from onboarding and integration, to dispute handling, risk control and payment success rate operation; Domain-trained intelligence functions like a virtual team of payment experts to manage traditionally resource-intensive
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 07:00:00 CET | Press release
OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial) become available across Europe as of December 2025 and January 2026, respectivelyMarks Samsung Bioepis’ 10th and 11th biosimilars launched in Europe and second and third product to be commercialized directly by Samsung BioepisLaunch reinforces Samsung Bioepis’ biosimilar leadership in Europe as it expands its portfolio into endocrinology and builds on its growing direct sales efforts Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a pa
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 22:31:00 CET | Press release
The world’s first assessment to assess AI models’ alignment with Emirati identity and values The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. F
GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system28.11.2025 12:00:00 CET | Press release
FOR USE IN CE-MARK EUROPEAN COUNTRIES ONLY GE HealthCare announces CE Mark for its Omni 128cm total body PET/CT,i a next-generation imaging system designed to advance precision care as well as cancer diagnosis, staging and treatment planning The new system is designed to accommodate head-to-thigh imaging in a single bed to improve workflow and efficiency, and enable a significant reduction in dose/scan time – all important factors, especially for populations like pediatric patients Built for both clinical and research excellence, the system may support the development and evaluation of new clinical pathways, novel PET tracers and emerging theranostic agents GE HealthCare today announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system,i a major milestone in its mission to advance precision care. Designed to advance cancer diagnosis, staging, therapeutic planning and treatment response monitoring, this innovative sy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom